| Identification | Back Directory | [Name]
(R)-MG132 | [CAS]
1211877-36-9 | [Synonyms]
(R)-MG132
MG-132(R)
MG-132(S,R,S)
(S,R,S)-(-)-MG-132
Z-Leu-D-leu-leu-al
Cbz-L-leu-D-leu-L-leu-H
N-[(Phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-D-leucinamide
D-Leucinamide, N-[(phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-
benzyl N-[(2S)-4-methyl-1-[[(2R)-4-methyl-1-[[(2S)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamate | [Molecular Formula]
C26H41N3O5 | [MDL Number]
MFCD28580122 | [MOL File]
1211877-36-9.mol | [Molecular Weight]
475.62 |
| Hazard Information | Back Directory | [Description]
The ubiquitin-proteasome pathway plays an integral role in the selective degradation of intracellular proteins. While important for clearing damaged or mis-folded proteins, this proteolytic pathway also regulates the availability of key proteins involved in the control of inflammatory processes, cell cycle regulation, and gene expression.1,2 (R)-MG132 is a potent, reversible, and cell permeable proteasome inhibitor. After treatment for one hour at 100 nM, it inhibits 50% and 31% of proteasome activity in lysates of J558L multiple myeloma cells and EMT6 breast cancer cells, respectively.3 The (R)-MG132 stereoisomer is a more effective inhibitor of chymotrypsin-like (ChTL), trypsin-like (TL), and peptidylglutamyl peptide hydrolyzing proteasome (PGPH) activities compared to (S)-MG132 (IC50s = 0.22 versus 0.89 μM (ChTL); 34.4 versus 104.43 μM (TL); 2.95 versus 5.70 μM (PGPH), respectively).3 | [Uses]
(R)-MG-132 is a potent, reversible and selective tripeptide aldehyde proteasome inhibitor. | [Uses]
(R)-MG132 has been used in ubiquitination assay and is used as a proteasome inhibitor. | [Definition]
ChEBI: D-leucinamide, n-[(phenylmethoxy)carbonyl]-l-leucyl-n-[(1s)-1-formyl-3-methylbutyl]- is a peptide. | [Biochem/physiol Actions]
MG132 (carbobenzoxy-Leu-Leu-leucinal) is a tri-peptide aldehyde. It possesses antitumor activity and boosts cytostatic/cytotoxic effects of chemo- and radiotherapy. (R)-MG132 is a potent, membrane-permeable proteasome inhibitor. It can inhibit proteasome activity in lysates of J558L multiple myeloma cells and EMT6 breast cancer cells. The (R)-MG132 stereoisomer is a more effective inhibitor of chymotrypsin-like (ChTL), trypsin-like (TL), and peptidylglutamyl peptide hydrolyzing proteasome (PGPH) activities than the (S)-MG132. | [storage]
Store at -20°C |
|
|